Evidence map›Paper›PMID 31725894›Full record

ArticleBlood advances2019

Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.

Benjamin A Derman, Keriann Kordas, Jean Ridgeway, Selina Chow, William Dale, Sang Mee Lee, Elingel Aguada, Andrzej J Jakubowiak, Jagoda Jasielec, Justin Kline and 10 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 5 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 5 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Guideline
  4. Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Benjamin A DermanSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Keriann KordasSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Jean RidgewaySection of Hematology/Oncology, University of Chicago, Chicago, IL.
Selina ChowSection of Hematology/Oncology, University of Chicago, Chicago, IL.
William DaleDepartment of Supportive Care Medicine, City of Hope, Duarte, CA.
Sang Mee LeeDepartment of Health Studies and.
Elingel AguadaSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Andrzej J JakubowiakSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Jagoda JasielecSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Justin KlineSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Satyajit KosuriSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Richard A LarsonSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Hongtao LiuSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Mylove MortelSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Olatoyosi OdenikeSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Jennifer PisanoSection of Infectious Diseases, University of Chicago, Chicago, IL; and.
Peter RiedellSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Wendy StockSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Michael R BishopSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Andrew S ArtzDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
University of Chicago · USCity of Hope · USAbbVie (United States) · US

Funding

BASIC RESEARCH TRAINING IN MEDICAL ONCOLOGYT32CA009566 · NCI · UNIVERSITY OF CHICAGO · PI OLUFUNMILAYO F. OLOPADE · 1987 to 2026
$10.5M
NCI NIH HHS T32 CA009566
6 · The paper itself

Abstract

Limitations found on geriatric assessment (GA) track with worse outcomes after hematopoietic cell transplantation (HCT). We report on a multidisciplinary team clinic (MDC), consisting of a cancer-specific GA and a multidisciplinary team of providers, to assess candidacy and create an individualized optimization plan for allogeneic HCT candidates aged ≥60 years and autologous HCT and adoptive T-cell therapy candidates aged ≥70 years. Among the 247 patients evaluated in the MDC, allogeneic HCT candidates comprised the majority (60%), followed by autologous HCT (37%) with occasional older cellular therapy candidates (3%). Almost all patients meeting program-required minimum ages for MDC optimization at our institution were assessed (98%). Relative to historical control subjects undergoing GA alone, allogeneic HCT patients aged ≥60 years who underwent MDC appraisal had similar frequencies of high-risk disease, reduced intensity regimens, and high comorbidity but fewer GA-graded functional impairments. The MDC cohort experienced fewer inpatient deaths, shorter length of stay, and fewer discharges to nursing facilities compared with control subjects. Improvements in early mortality were observed over time; 1-year overall survival improved from 43% in the pre-MDC era to 70% in the recent MDC era, and 1-year nonrelapse mortality decreased from 43% to 18%. The 31 autologous HCT recipients aged ≥70 years optimized by the MDC achieved 0% nonrelapse mortality and 97% overall survival at 1 year. A GA-guided MDC for older HCT candidates is feasible and seems to reduce transplant-associated morbidity and mortality. An MDC should encourage broader and safer utilization of transplantation in older patients.

Indexed as

Disease ManagementGeriatric AssessmentInterdisciplinary CommunicationPatient Care TeamPreoperative CareAdultAgedAged, 80 and overClinical Decision-MakingFemaleHealth Plan ImplementationHealth Planning GuidelinesHematopoietic Stem Cell TransplantationHumansMaleMiddle Aged

Identifiers

PMID31725894
PMCPMC6880895
OpenAlexW2983381086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.